Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?
Direct-acting antivirals (DAA) have revolutionized the treatment of patients with chronic hepatitis C virus (HCV) infection, possibly leading to HCV elimination by 2030 as endorsed by the World Health Organization (WHO). However, some patients belonging to the so-called unique or special populations...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/13/6/1048 |
| _version_ | 1797531753757278208 |
|---|---|
| author | Virginia Solitano Maria Corina Plaz Torres Nicola Pugliese Alessio Aghemo |
| author_facet | Virginia Solitano Maria Corina Plaz Torres Nicola Pugliese Alessio Aghemo |
| author_sort | Virginia Solitano |
| collection | DOAJ |
| description | Direct-acting antivirals (DAA) have revolutionized the treatment of patients with chronic hepatitis C virus (HCV) infection, possibly leading to HCV elimination by 2030 as endorsed by the World Health Organization (WHO). However, some patients belonging to the so-called unique or special populations are referred to as difficult-to-treat due to unreached sustained virological response, potential drug side effects or interactions or co-morbidities. Several years after the DAA introduction and on the basis of excellent findings in terms of efficacy and safety, some doubts arise around the exact meaning of the special population designation and whether this group of patients actually exists. The aim of this review is to discuss and analyze current evidence on the management and treatment of the so-called “unique populations”. We placed particular emphasis on patients with decompensated cirrhosis, chronic kidney disease (CKD), coinfections, rare genotypes, and previous treatment failure, in order to provide physicians with an updated overview of the actual problems and needs in the current scenario. |
| first_indexed | 2024-03-10T10:49:15Z |
| format | Article |
| id | doaj.art-da5b47793c704a348d5a5da4d1b47e8f |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T10:49:15Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-da5b47793c704a348d5a5da4d1b47e8f2023-11-21T22:24:38ZengMDPI AGViruses1999-49152021-06-01136104810.3390/v13061048Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?Virginia Solitano0Maria Corina Plaz Torres1Nicola Pugliese2Alessio Aghemo3Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20082 Milan, ItalyDivision of Internal Medicine and Hepatology, Humanitas Research Hospital IRCCS, Rozzano, 20089 Milan, ItalyDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20082 Milan, ItalyDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20082 Milan, ItalyDirect-acting antivirals (DAA) have revolutionized the treatment of patients with chronic hepatitis C virus (HCV) infection, possibly leading to HCV elimination by 2030 as endorsed by the World Health Organization (WHO). However, some patients belonging to the so-called unique or special populations are referred to as difficult-to-treat due to unreached sustained virological response, potential drug side effects or interactions or co-morbidities. Several years after the DAA introduction and on the basis of excellent findings in terms of efficacy and safety, some doubts arise around the exact meaning of the special population designation and whether this group of patients actually exists. The aim of this review is to discuss and analyze current evidence on the management and treatment of the so-called “unique populations”. We placed particular emphasis on patients with decompensated cirrhosis, chronic kidney disease (CKD), coinfections, rare genotypes, and previous treatment failure, in order to provide physicians with an updated overview of the actual problems and needs in the current scenario.https://www.mdpi.com/1999-4915/13/6/1048hepatitis Cunique populationsspecial populationsdecompensated cirrhosischronic kidney diseaseend stage renal disease |
| spellingShingle | Virginia Solitano Maria Corina Plaz Torres Nicola Pugliese Alessio Aghemo Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations? Viruses hepatitis C unique populations special populations decompensated cirrhosis chronic kidney disease end stage renal disease |
| title | Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations? |
| title_full | Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations? |
| title_fullStr | Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations? |
| title_full_unstemmed | Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations? |
| title_short | Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations? |
| title_sort | management and treatment of hepatitis c are there still unsolved problems and unique populations |
| topic | hepatitis C unique populations special populations decompensated cirrhosis chronic kidney disease end stage renal disease |
| url | https://www.mdpi.com/1999-4915/13/6/1048 |
| work_keys_str_mv | AT virginiasolitano managementandtreatmentofhepatitiscaretherestillunsolvedproblemsanduniquepopulations AT mariacorinaplaztorres managementandtreatmentofhepatitiscaretherestillunsolvedproblemsanduniquepopulations AT nicolapugliese managementandtreatmentofhepatitiscaretherestillunsolvedproblemsanduniquepopulations AT alessioaghemo managementandtreatmentofhepatitiscaretherestillunsolvedproblemsanduniquepopulations |